Navigation Links
Genzyme Reports Strong First-Quarter Growth
Date:4/23/2008

ty method

investments 188 5,612

Minority interest 463 3,912

Gain (loss) on investments in

equity securities (3) 775 12,788

Other (160) (525)

Investment income 14,870 16,219

Interest expense (1,655) (4,188)

Total other income (expenses) 14,481 33,818

Income (loss) before income taxes (1) 205,388 229,380

(Provision for) benefit from income

taxes (1) (60,117) (71,193)

Net income (loss) (1) $145,271 $158,187

Net income (loss) per share:

Basic $0.54 $0.60

Diluted (1,4) $0.52 $0.57

Weighted average shares outstanding:

Basic 267,276 263,476

Diluted (1,4) 285,208 279,924

(1) In accordance with the provisions of Financial Accounting Standards

Board, or FASB, Statement of Financial Accounting Standards No., or

FAS, 123R, "Share-Based Payment, an amendment of FASB Statement Nos.

123 and 95," we recorded pre-tax charges for stock-based compensation

expense and related tax benefits of:

Three Months Ended

March 31,

2008 2007

Cost of products and services sold $(6,514) $(5,896)

Selling, general and administrative


'/>"/>
SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Genzyme to Build New R&D Center in Beijing
2. Genzyme Provides Update on Myozyme(R) Manufacturing
3. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
4. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
5. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
6. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
7. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
8. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
9. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
10. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
11. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... FLORHAM PARK, N.J. , March 30, 2015 ... antagonist (PAMORA) under development by Shionogi & Co., ... a phase III study (COMPOSE I) for the ... with chronic non-cancer pain receiving opioid therapy. Study ... once daily) statistically significantly improved the frequency of ...
(Date:3/29/2015)... 29, 2015  Caris Life Sciences® today announced ... Molecular Intelligence®, the company,s panomic, comprehensive tumor profiling ... several rare and difficult to treat gynecological cancers ... potential to improve patient outcomes. These studies were ... Society of Gynecologic Oncology (SGO) 2015 Annual Meeting ...
(Date:3/29/2015)... (PRWEB) March 29, 2015 As a ... often required by our pharmaceutical manufacturing clients, Whitehouse Laboratories ... sponsorship of the Berkenstock Race Team for the 2015 ... not only speed, but a strong sense of precision ... that lead to success in the quality control testing ...
(Date:3/27/2015)... , 27. März 2015  Peter Walter ... Biomedical Science für seine bahnbrechende Arbeit ausgewählt, ... Zellkompartimenten transportiert werden, sowie für die Entschlüsselung ... Reaktion auf Stress nutzen, der mit der ... ist Professor für Biochemie an der University ...
Breaking Biology Technology:Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 2Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 3Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 4Whitehouse Laboratories Reaffirms Commitment to Speedy Results – Renews Sponsorship of Berkenstock Racing Team 2Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 2Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 3Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 4
... -Company,s New Name is PROLOR Biotech, Inc.- , , ... -Shareholders Approve Re-Election of Board of Directors and Other Proposals- ... (OTC Bulletin Board: MODG) today announced that shareholders approved a ... at its Annual Meeting of Shareholders held on May 21, ...
... sale in the United Statesfor treatment of pain and fever ... Cumberland Pharmaceuticals ( www.cumberlandpharma.com ) today announced ... Caldolor(TM) , an intravenous formulation of ibuprofen, through a priority ... for sale in the United States for the treatment of ...
... SEATTLE, June 11 ... results of a,large-scale Phase III study of Circadin(R) ... efficacy and safety in elderly patients.,The results were ... SLEEP,2009, the 23rd Annual Meeting of the Associated ...
Cached Biology Technology:Modigene Shareholders Approve Company Name Change and Other Proposals at Annual Meeting 2Cumberland Pharmaceuticals Announces FDA Approval of Caldolor(TM) 2Cumberland Pharmaceuticals Announces FDA Approval of Caldolor(TM) 3Neurim Pharmaceuticals Reports Long Term Efficacy and Safety for Circadin(R) for Insomnia in Elderly Patients 2
(Date:3/10/2015)... PROVO, Utah , March 10, 2015   ... genome interpretation, has been selected by next-generation sequencing company ... provider of whole exome and targeted gene panel interpretation. ... sequencing provider, has adopted the most current technologies to ... of genetic research. The company offers two types of ...
(Date:3/5/2015)... 5, 2015 In Brazil , ... already using these solutions and 42 percent planning to invest ... approximately 25 percent of the companies will be investing in ... majority of companies in the region are currently opting for ... model will command significant attention in the coming years. This ...
(Date:3/3/2015)... FOREST, Calif. , March 3, 2015 ... the leading provider of advanced cryogenic logistics ... markets including immunotherapies, stem cells, cell lines, ... and reproductive medicine, today announced the expansion ... Cancer Research Centers, ("Fred Hutch") Clinical ...
Breaking Biology News(10 mins):PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 2PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 2Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 4Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3
... in the United States National Museum of Natural History ... Insects, researchers have found 16 new species of wasps ... species. The new species are described and illustrated ... a Key of the Charipinae (Hymenoptera: Cynipoidea: Figitidae) From ...
... recommendations is weak among people suffering from metabolic syndrome ... the Nordic SYSDIET study led by the University of ... high in salt and saturated fat, and too low ... have a sufficient intake of vitamin D. Metabolic syndrome ...
... can cause functional inhibition of remote regions such ... diaschisis. This phenomenon is often analyzed using positron ... these methods are expensive and radioactive. Dr. Yunjun ... Wenzhou Medical University in China quantified the changes ...
Cached Biology News:Nordic study: Few persons with metabolic syndrome adhere to nutrition recommendations 2